Fig. 2: Pre-treatment of ZLDI-8 enhances the inhibitory activation of Sorafenib on MHCC97-H cells’ in vitro invasion and migration. | Cell Death & Disease

Fig. 2: Pre-treatment of ZLDI-8 enhances the inhibitory activation of Sorafenib on MHCC97-H cells’ in vitro invasion and migration.

From: Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells

Fig. 2

MHCC97-H cells, which were pretreated with 1 μmol/L ZLDI-8 or solvent control (1‰ DMSO), were treated with the IC50 concentration of Sorafenib. Cells were then harvested and analyzed for trans-well assays. The invasion a and migration b of MHCC97-H cells were shown as the represented photographs or the relative invasion/migration cell numbers. *p < 0.05 vs. Sorafenib or control; *p < 0.05 vs. ZLDI-8 or control

Back to article page